Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
11 p, 388.8 KB Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab / Arnold, D (Instituto CUF de Oncologia (I.C.O.), Lisboa) ; Fuchs, C S (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona) ; Ohtsu, A (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Zhu, A X (Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA) ; Garon, E B (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ; Mackey, J R (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ; Paz Ares, L (Hospital Universitario Doce de Octubre. Departamento de Oncologia Médica) ; Baron, A D (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ; Okusaka, T (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ; Yoshino, T (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Yoon, H H (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ; Das, M (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, D (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Binder, P (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Sashegyi, A (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Chau, I (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of Oncology, Vol. 28 (september 2017) , p. 2932-2942  
2.
9 p, 1.1 MB Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab / Fuchs, Charles S (Dana-Farber Cancer Institute. Harvard Medical School) ; Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Tomášek, Jiří (Masaryk University. Masaryk Memorial Cancer Institute (Czech Republic)) ; Chau, Ian (Royal Marsden Hospital (United Kingdom)) ; Melichar, Bohuslav (Univerzity Palackeho a Fakultni nemocnice. Onkologicka klinika (Czech Republic)) ; Safran, Howard (Brown University Oncology Research Group (USA)) ; Tehfe, Mustapha A (Centre Hospitalier de Montréal (Canada)) ; Filip, Dumitru (Spitalul Judetean de Urgenta (Romania)) ; Topuzov, Eldar (Northwest State Medical University na II Mechnikov. State Budgetary Educational Institution of Higher Professional Education (SBEIHPE). Ministry of Healthcare of the Russian Federation) ; Schlittler, Luis (Hospital da Cida de Passo Fundo (Brasil)) ; Udrea, Anghel Adrian (Medisprof SRL (Romania)) ; Campbell, William (Hospital Herrera Llerandi (Guatemala)) ; Brincat, Stephen (Sir Anthony Mamo Oncology Centre (Malta)) ; Emig, Michael (Lilly Deutschland GmbH (Germany)) ; Melemed, Symantha A (Eli Lilly and Company. Lilly Corporate Center (USA)) ; Hozak, Rebecca R (Eli Lilly and Company. Lilly Corporate Center (USA)) ; Ferry, David (Eli Lilly and Company (USA)) ; Caldwell, C William (Eli Lilly and Company. Lilly Corporate Center (USA)) ; Ajani, Jaffer A (The University of Texas MD Anderson Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. [...]
2016 - 10.1038/bjc.2016.293
British Journal of Cancer, Vol. 115, Issue 8 (October 2016) , p. 974-982  

Vea también: autores con nombres similares
2 Fuchs, Charles
1 Fuchs, Charles S
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.